MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Recruiting now
Conditions studied: Tenosynovial Giant Cell Tumor
In brief
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
Key facts
- Study ID
- NCT07075471
- Run by
- Deciphera Pharmaceuticals, LLC
- People needed
- 100
- Starts
- 2025-09-03
- Expected to finish
- 2027-09-01
- Last updated by the study team
- 2026-07-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of TGCT according to medical records
- Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.
- Has provided informed consent and medical records release
You may not qualify if…
- Participant is active in an interventional clinical trial of vimseltinib
Where it is running
- Synexus Clinical Research, US INC — Wilmington, North Carolina, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.